New Stock News | DeShi Biotechnology submits application for listing on the Hong Kong Stock Exchange. The company's self-developed iMedImage universal medical imaging platform model has successfully achieved commercialization.

According to the disclosure by the Hong Kong Stock Exchange on June 29th, Hangzhou Deshi Biological Technology Co., Ltd. (referred to as Deshi Bio) has submitted an application for listing on the main board of the Hong Kong Stock Exchange, with Huatai International as the exclusive sponsor. According to the prospectus, based on Frost & Sullivan data, Deshi Bio's independently developed iMedImageTM is the world's largest universal medical image base model in terms of parameter scale, has been successfully commercialized, and has been recognized as the world's first commercially available cross-modal medical image base model. Deshi Bio has always focused on the medical imaging AI industry. The company's proprietary iMedImageTM has a cross-modal pre-training architecture that enables a single unified model to support 19 medical imaging modalities (such as chromosomes, CT scans, MRIs, ultrasounds, and pathology) and covers over 90% of clinical medical imaging scenarios, including reproductive health, hematologic malignancies, and radiation hygiene. With its unified foundational capabilities, strong generalization abilities, and extendable architectural tools, iMedImageTM powers multi-modal, multi-task, and multi-scene AI solutions. These solutions significantly reduce research and development costs and time to market, address uneven distribution of medical resources, improve diagnostic efficiency, and provide an innovative path for scalable intelligent healthcare. By leveraging the iMedImageTM medical image base model, Deshi Bio provides an end-to-end AI medical imaging solution combination of "base model-intelligent medical devices-reagents and consumables-large model services", meeting the full-cycle needs from the laboratory to clinical settings. According to Frost & Sullivan data, after obtaining approval from the National Medical Products Administration, the company's core product AI AutoVision is expected to be the world's first and only AI-driven chromosomal karyotype analysis-assisted diagnostic system. According to Frost & Sullivan data, after obtaining approval from the National Medical Products Administration, AI AutoVision is expected to become the world's first AI-driven system for automatic identification and prompt of chromosomal abnormalities, achieving Level 3 intelligence, setting a new benchmark for intelligent chromosomal karyotype analysis. AI AutoVision was recognized by the National Medical Products Administration as a "Class III Innovative Medical Device" in May 2025 and can enjoy an accelerated regulatory approval process. It has successfully completed clinical trials and submitted a Class III medical device registration application to the National Medical Products Administration in May 2025. In June 2025, the company received an "Acceptance Notification" from the National Medical Products Administration, indicating that the registration application has been formally accepted. In terms of finances, in the years 2023 and 2024, Deshi Bio achieved revenues of approximately 52.844 million RMB and 70.352 million RMB, respectively; while in the same period, it incurred losses of 56.116 million RMB and 43.375 million RMB, respectively.